Stocktoria
Gossamer Bio, Inc. GOSS
Gossamer Bio, Inc. (GOSS) earns a Piotroski F-score of 0/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $48.5M at a -351.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 0/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| GOSS | Gossamer Bio, Inc. | 0/9 | — | — | -57.7% |
| LXRX | LEXICON PHARMACEUTICALS, INC. | 3/9 | — | — | +60.2% |
| PTGX | Protagonist Therapeutics, Inc | 4/9 | 13.41 | — | -89.4% |
| SEPN | Septerna, Inc. | 4/9 | 3.75 | — | — |
| OCUL | OCULAR THERAPEUTIX, INC | 3/9 | 3.49 | — | -18.5% |
| XOMA | XOMA Royalty Corp | 5/9 | -11.82 | 23.3 | +83.1% |
| AQST | Aquestive Therapeutics, Inc. | 2/9 | -8.08 | — | -22.6% |
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
FAQ
Is GOSS financially healthy?
Gossamer Bio, Inc.'s Piotroski F-score is 0/9 (8–9 is excellent, 0–3 weak).
Does GOSS pay a dividend?
No, Gossamer Bio, Inc. does not currently pay a dividend.
How profitable is GOSS?
In FY2025, Gossamer Bio, Inc. had a net margin of -351.5%.
What is the analyst price target for GOSS?
The average Wall-Street price target for Gossamer Bio, Inc. is $3.86, about 2071.2% above the recent price, from 5 analysts (consensus: hold).
Is GOSS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Gossamer Bio, Inc.: a Piotroski F-score of 0/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.